請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7067
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王勝仕(Sheng-Shih Wang) | |
dc.contributor.author | Yi-Fan Liao | en |
dc.contributor.author | 廖宜凡 | zh_TW |
dc.date.accessioned | 2021-05-17T10:18:09Z | - |
dc.date.available | 2021-05-17T10:18:09Z | - |
dc.date.issued | 2011 | |
dc.date.submitted | 2012-08-16 | |
dc.identifier.citation | 1 Ross, C. A. & Poirier, M. A. Protein aggregation and neurodegenerative disease. Nature medicine 10 Suppl, S10-17, doi:10.1038/nm1066 (2004).
2 Sipe, J. D. et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 17, 101-104, doi:10.3109/13506129.2010.526812 (2010). 3 Pettersson-Kastberg, J. et al. Can misfolded proteins be beneficial? The HAMLET case. Annals of medicine 41, 162-176, doi:10.1080/07853890802502614 (2009). 4 Berchtold, N. C. & Cotman, C. W. Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiology of aging 19, 173-189 (1998). 5 Tiraboschi, P., Hansen, L. A., Thal, L. J. & Corey-Bloom, J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62, 1984-1989 (2004). 6 Thinakaran, G. & Koo, E. H. Amyloid precursor protein trafficking, processing, and function. The Journal of biological chemistry 283, 29615-29619, doi:10.1074/jbc.R800019200 (2008). 7 Suh, Y. H. & Checler, F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacological reviews 54, 469-525 (2002). 8 Zheng, H. & Koo, E. H. The amyloid precursor protein: beyond amyloid. Molecular neurodegeneration 1, 5, doi:10.1186/1750-1326-1-5 (2006). 9 Hardy, J. A. & Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185 (1992). 10 Prabhulkar, S., Piatyszek, R., Cirrito, J. R., Wu, Z. Z. & Li, C. Z. Microbiosensor for Alzheimer's disease diagnostics: detection of amyloid beta biomarkers. Journal of neurochemistry, doi:10.1111/j.1471-4159.2012.07709.x (2012). 11 Al-Ayadhi, L. Y., Ben Bacha, A. G., Kotb, M. & El-Ansary, A. K. A novel study on amyloid beta peptide 40, 42 and 40/42 ratio in Saudi autistics. Behavioral and brain functions : BBF 8, 4, doi:10.1186/1744-9081-8-4 (2012). 12 Ahmed, M. et al. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nature structural & molecular biology 17, 561-567, doi:10.1038/nsmb.1799 (2010). 13 Sakono, M. & Zako, T. Amyloid oligomers: formation and toxicity of Abeta oligomers. The FEBS journal 277, 1348-1358, doi:10.1111/j.1742-4658.2010.07568.x (2010). 14 Brorsson, A. C. et al. Methods and models in neurodegenerative and systemic protein aggregation diseases. Frontiers in bioscience : a journal and virtual library 15, 373-396 (2010). 15 From molecular mechanisms toward the cure of systemic amyloidoses. Abstracts of the XII International Symposium on Amyloidosis. April 18-21, 2010. Rome, Italy. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 17 Suppl 1, 38-207, doi:10.3109/13506121003737385 (2010). 16 Laboratory of neurobiology and neuropharmacologyof aging and neurodegenerative diseases. 17 Alzheimer Disease & Frontotemporal Dementia Mutation Database. 18 Reaume, A. G. et al. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a 'humanized' Abeta sequence. The Journal of biological chemistry 271, 23380-23388 (1996). 19 Hori, Y. et al. The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate Abeta fibril formation without increasing protofibril formation. The Journal of biological chemistry 282, 4916-4923, doi:10.1074/jbc.M608220200 (2007). 20 Ono, K., Condron, M. M. & Teplow, D. B. Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity. The Journal of biological chemistry 285, 23186-23197, doi:10.1074/jbc.M109.086496 (2010). 21 Wakutani, Y. et al. Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry 75, 1039-1042 (2004). 22 Chen, W. T. et al. Amyloid-beta (Abeta) D7H mutation increases oligomeric Abeta42 and alters properties of Abeta-zinc/copper assemblies. PloS one 7, e35807, doi:10.1371/journal.pone.0035807 (2012). 23 De Jonghe, C. et al. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiology of disease 5, 281-286, doi:10.1006/nbdi.1998.0202 (1998). 24 Levy, E., Prelli, F. & Frangione, B. Studies on the first described Alzheimer's disease amyloid beta mutant, the Dutch variant. Journal of Alzheimer's disease : JAD 9, 329-339 (2006). 25 Tsubuki, S., Takaki, Y. & Saido, T. C. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 361, 1957-1958 (2003). 26 Lord, A. et al. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiology of aging 27, 67-77, doi:10.1016/j.neurobiolaging.2004.12.007 (2006). 27 Van Nostrand, W. E., Melchor, J. P., Cho, H. S., Greenberg, S. M. & Rebeck, G. W. Pathogenic effects of D23N Iowa mutant amyloid beta -protein. The Journal of biological chemistry 276, 32860-32866, doi:10.1074/jbc.M104135200 (2001). 28 Ancolio, K. et al. Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 96, 4119-4124 (1999). 29 Cruts, M. et al. Novel APP mutation V715A associated with presenile Alzheimer's disease in a German family. Journal of neurology 250, 1374-1375, doi:10.1007/s00415-003-0182-5 (2003). 30 Eckman, C. B. et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Human molecular genetics 6, 2087-2089 (1997). 31 Hardy, J. Amyloid, the presenilins and Alzheimer's disease. Trends in neurosciences 20, 154-159 (1997). 32 Roher, A. E. et al. The human amyloid-beta precursor protein770 mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates. The Journal of biological chemistry 279, 5829-5836, doi:10.1074/jbc.M311380200 (2004). 33 Kwok, J. B. et al. Novel Leu723Pro amyloid precursor protein mutation increases amyloid beta42(43) peptide levels and induces apoptosis. Annals of neurology 47, 249-253 (2000). 34 Janssen, J. C. et al. Early onset familial Alzheimer's disease: Mutation frequency in 31 families. Neurology 60, 235-239 (2003). 35 Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L. & Markesbery, W. R. Copper, iron and zinc in Alzheimer's disease senile plaques. Journal of the neurological sciences 158, 47-52 (1998). 36 Bush, A. I., Masters, C. L. & Tanzi, R. E. Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. Proceedings of the National Academy of Sciences of the United States of America 100, 11193-11194, doi:10.1073/pnas.2135061100 (2003). 37 Kowalik-Jankowska, T., Ruta-Dolejsz, M., Wisniewska, K., Lankiewicz, L. & Kozlowski, H. Possible involvement of copper(II) in Alzheimer disease. Environmental health perspectives 110 Suppl 5, 869-870 (2002). 38 Mantyh, P. W. et al. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. Journal of neurochemistry 61, 1171-1174 (1993). 39 Esler, W. P. et al. Zinc-induced aggregation of human and rat beta-amyloid peptides in vitro. Journal of neurochemistry 66, 723-732 (1996). 40 Schrag, M., Mueller, C., Oyoyo, U., Smith, M. A. & Kirsch, W. M. Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Progress in neurobiology 94, 296-306, doi:10.1016/j.pneurobio.2011.05.001 (2011). 41 Maynard, C. J., Bush, A. I., Masters, C. L., Cappai, R. & Li, Q. X. Metals and amyloid-beta in Alzheimer's disease. International journal of experimental pathology 86, 147-159, doi:10.1111/j.0959-9673.2005.00434.x (2005). 42 Azimi, S. & Rauk, A. On the involvement of copper binding to the N-terminus of the amyloid Beta Peptide of Alzheimer's disease: a computational study on model systems. International journal of Alzheimer's disease 2011, 539762, doi:10.4061/2011/539762 (2011). 43 Karr, J. W., Akintoye, H., Kaupp, L. J. & Szalai, V. A. N-Terminal deletions modify the Cu2+ binding site in amyloid-beta. Biochemistry 44, 5478-5487, doi:10.1021/bi047611e (2005). 44 Minicozzi, V. et al. Identifying the minimal copper- and zinc-binding site sequence in amyloid-beta peptides. The Journal of biological chemistry 283, 10784-10792, doi:10.1074/jbc.M707109200 (2008). 45 Budimir, A. Metal ions, Alzheimer's disease and chelation therapy. Acta Pharm 61, 1-14, doi:10.2478/v10007-011-0006-6 (2011). 46 Stellato, F. et al. Metal binding in amyloid beta-peptides shows intra- and inter-peptide coordination modes. European biophysics journal : EBJ 35, 340-351, doi:10.1007/s00249-005-0041-7 (2006). 47 Dong, J. et al. Engineering metal ion coordination to regulate amyloid fibril assembly and toxicity. Proceedings of the National Academy of Sciences of the United States of America 104, 13313-13318, doi:10.1073/pnas.0702669104 (2007). 48 Karr, J. W. & Szalai, V. A. Cu(II) binding to monomeric, oligomeric, and fibrillar forms of the Alzheimer's disease amyloid-beta peptide. Biochemistry 47, 5006-5016, doi:10.1021/bi702423h (2008). 49 Drew, S. C., Noble, C. J., Masters, C. L., Hanson, G. R. & Barnham, K. J. Pleomorphic copper coordination by Alzheimer's disease amyloid-beta peptide. Journal of the American Chemical Society 131, 1195-1207, doi:10.1021/ja808073b (2009). 50 Chen, Y. R. et al. The effect of Abeta conformation on the metal affinity and aggregation mechanism studied by circular dichroism spectroscopy. Journal of biochemistry 139, 733-740, doi:10.1093/jb/mvj083 (2006). 51 Tougu, V., Tiiman, A. & Palumaa, P. Interactions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity. Metallomics : integrated biometal science 3, 250-261, doi:10.1039/c0mt00073f (2011). 52 Shin, B. K. & Saxena, S. Substantial contribution of the two imidazole rings of the His13-His14 dyad to Cu(II) binding in amyloid-beta(1-16) at physiological pH and its significance. The journal of physical chemistry. A 115, 9590-9602, doi:10.1021/jp200379m (2011). 53 Alies, B. et al. pH-Dependent Cu(II) coordination to amyloid-beta peptide: impact of sequence alterations, including the H6R and D7N familial mutations. Inorganic chemistry 50, 11192-11201, doi:10.1021/ic201739n (2011). 54 Furlan, S. & La Penna, G. Modeling of the Zn2+ binding in the 1-16 region of the amyloid beta peptide involved in Alzheimer's disease. Physical chemistry chemical physics : PCCP 11, 6468-6481, doi:10.1039/b822771c (2009). 55 Kowalik-Jankowska, T., Ruta, M., Wisniewska, K. & Lankiewicz, L. Coordination abilities of the 1-16 and 1-28 fragments of beta-amyloid peptide towards copper(II) ions: a combined potentiometric and spectroscopic study. Journal of inorganic biochemistry 95, 270-282 (2003). 56 Garzon-Rodriguez, W., Yatsimirsky, A. K. & Glabe, C. G. Binding of Zn(II), Cu(II), and Fe(II) ions to Alzheimer's A beta peptide studied by fluorescence. Bioorganic & medicinal chemistry letters 9, 2243-2248 (1999). 57 Ma, Q. F. et al. Characterization of copper binding to the peptide amyloid-beta(1-16) associated with Alzheimer's disease. Biopolymers 83, 20-31, doi:10.1002/bip.20523 (2006). 58 Guilloreau, L. et al. Structural and thermodynamical properties of CuII amyloid-beta16/28 complexes associated with Alzheimer's disease. Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 11, 1024-1038, doi:10.1007/s00775-006-0154-1 (2006). 59 Raman, B. et al. Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide. The Journal of biological chemistry 280, 16157-16162, doi:10.1074/jbc.M500309200 (2005). 60 Danielsson, J., Pierattelli, R., Banci, L. & Graslund, A. High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide. The FEBS journal 274, 46-59, doi:10.1111/j.1742-4658.2006.05563.x (2007). 61 Tougu, V., Karafin, A. & Palumaa, P. Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid-beta peptide. Journal of neurochemistry 104, 1249-1259, doi:10.1111/j.1471-4159.2007.05061.x (2008). 62 Hatcher, L. Q., Hong, L., Bush, W. D., Carducci, T. & Simon, J. D. Quantification of the binding constant of copper(II) to the amyloid-beta peptide. The journal of physical chemistry. B 112, 8160-8164, doi:10.1021/jp710806s (2008). 63 Hou, L. & Zagorski, M. G. NMR reveals anomalous copper(II) binding to the amyloid Abeta peptide of Alzheimer's disease. Journal of the American Chemical Society 128, 9260-9261, doi:10.1021/ja046032u (2006). 64 Talmard, C., Bouzan, A. & Faller, P. Zinc binding to amyloid-beta: isothermal titration calorimetry and Zn competition experiments with Zn sensors. Biochemistry 46, 13658-13666, doi:10.1021/bi701355j (2007). 65 Curtain, C. C. et al. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. The Journal of biological chemistry 276, 20466-20473, doi:10.1074/jbc.M100175200 (2001). 66 Intrinsic fluorescence. 67 Semisotnov, G. V. et al. Study of the 'molten globule' intermediate state in protein folding by a hydrophobic fluorescent probe. Biopolymers 31, 119-128, doi:10.1002/bip.360310111 (1991). 68 Cordeiro, Y., Lima, L. M., Gomes, M. P., Foguel, D. & Silva, J. L. Modulation of prion protein oligomerization, aggregation, and beta-sheet conversion by 4,4'-dianilino-1,1'-binaphthyl-5,5'-sulfonate (bis-ANS). The Journal of biological chemistry 279, 5346-5352, doi:10.1074/jbc.M312262200 (2004). 69 Circular dichroism. 70 Kay, L. E., Keifer, P. & Saarinen, T. Pure Absorption Gradient Enhanced Heteronuclear Single Quantum Correlation Spectroscopy with Improved Sensitivity. Journal of the American Chemical Society 114, 10663-10665 (1992). 71 Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685 (1970). 72 Schagger, H. Tricine-SDS-PAGE. Nature protocols 1, 16-22, doi:10.1038/nprot.2006.4 (2006). 73 SDS-PAGE. 74 Burnette, W. N. 'Western blotting': electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Analytical biochemistry 112, 195-203 (1981). 75 Western. 76 Pelley, J. W., Garner, C. W. & Little, G. H. A simple rapid biuret method for the estimation of protein in samples containing thiols. Analytical biochemistry 86, 341-343 (1978). 77 Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. Protein measurement with the Folin phenol reagent. The Journal of biological chemistry 193, 265-275 (1951). 78 Smith, P. K. et al. Measurement of protein using bicinchoninic acid. Analytical biochemistry 150, 76-85 (1985). 79 Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry 72, 248-254 (1976). 80 Tal, M., Silberstein, A. & Nusser, E. Why does Coomassie Brilliant Blue R interact differently with different proteins? A partial answer. The Journal of biological chemistry 260, 9976-9980 (1985). 81 Vollers, S. S., Teplow, D. B. & Bitan, G. Determination of Peptide oligomerization state using rapid photochemical crosslinking. Methods Mol Biol 299, 11-18 (2005). 82 ITC data analysis. 83 Finder, V. H., Vodopivec, I., Nitsch, R. M. & Glockshuber, R. The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42. Journal of molecular biology 396, 9-18, doi:10.1016/j.jmb.2009.12.016 (2010). 84 Chen, W. T., Liao, Y. H., Yu, H. M., Cheng, I. H. & Chen, Y. R. Distinct effects of Zn2+, Cu2+, Fe3+, and Al3+ on amyloid-beta stability, oligomerization, and aggregation: amyloid-beta destabilization promotes annular protofibril formation. The Journal of biological chemistry 286, 9646-9656, doi:10.1074/jbc.M110.177246 (2011). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7067 | - |
dc.description.abstract | 目前阿茲海默症的研究中指出,β-類澱粉蛋白(β-amyloid peptide)是造成阿茲海默症最主要的致病原因,類澱粉前驅蛋白(amyloid precursor protein, APP)經由兩種蛋白酵素水解以後產生β-類澱粉蛋白,而此種蛋白會在腦中造成不正常聚集(aggregation),形成具有神經毒性(neurotoxicity)的腦部斑塊(plaque),進一步造成神經細胞受損,此種學說稱之為類澱粉蛋白致病假說(amyloid cascade hypothesis)。
依照發生時間的不同,阿茲海默症又可被分為家族性(familial)及偶發性(sporadic)兩種,前者往往是因為遺傳突變基因導致早發性(early-onset)阿茲海默症的發生,且研究發現此類型患者其β-類澱粉蛋白聚集之機制往往與其他人有顯著的不同。 此外,對阿茲海默症患者的腦部研究後發現,在其斑塊中鋅、銅、鐵、鋁等金屬離子也發生堆積的現象,因此金屬離子被懷疑可能是誘導β-類澱粉蛋白產生聚集的可能因素之一。 本實驗為研究鋅、銅離子與原生型、及各種突變型β-類澱粉蛋白之間作用力,以試著找出金屬離子與β-類澱粉蛋白之鍵結結構(coordination),首先試著生產與純化15N標記的原生型及突變型β-類澱粉蛋白以進行1H-15N HSQC之實驗,然而由於TEV蛋白脢之切割產率過差,且最後HPLC之純化無法將帶有histag之融合蛋白有效分離,此實驗流程有待進一步之研究與改良,若假設蛋白脢之切割率為100%則約可獲得0.4mg/L之產率。 接下來試著以金屬離子對原生型及突變型的合成胜肽(synthetic peptide)進行滴定,並以各種光學法及ITC來比較其差異性。自身螢光的結果中顯示,在與鋅離子結合時,H6A及H6R兩種突變型與其他的突變型有明顯的差異。Bis-ANS螢光結果則可發現,當銅離子與β-類澱粉蛋白結合時,疏水性裸露區域減少,鋅離子與β-類澱粉蛋白結合時疏水性裸露區域則增加,可見鋅、銅離子與β-類澱粉蛋白之結合機制必定有所不同。而H6A、H6R與鋅離子結合之Bis-ANS光譜也可發現與其他類型蛋白有所不同。圓二色光譜之研究發現,β-類澱粉蛋白單體在利用氫氧化鈉去摺疊法製備時其二級結構為不規則形(random coil),在對鋅、銅離子滴定時未有發現顯著的二級結構變化。 本研究中也利用各種不同之結合公式擬合(fitting)自身螢光之滴定結果來探討金屬離子與不同β-類澱粉蛋白之解離係數,同時也將利用ITC滴定之結果以與其比較。最後發現整體結合公式(total binding equation)最能充分描述我們在自身螢光滴定實驗下所獲得的結果,原生型β-類澱粉蛋白與銅、鋅離子之解離常數分別為3.86、4.26μM,與ITC之結果3.79、4.27μM幾乎完全相同。 由本研究之結果發現,H6之突變型滴定曲線與其他類型相比確有較大之差異存在,然而是否代表其鍵結機構不同於其他類型,仍有待進一步查證。我們認為,若能完成光誘導交聯法及二維異核化學位移相關光譜之結果必能更進一步確認實驗之結果。 | zh_TW |
dc.description.abstract | The previous studies show that β-amyloid peptide(Aβ), the product from amyloid precursor protein (APP) cut by two secretase sequentially, is the major cause of Alzheimer’s disease (AD). Misfolding of this peptide can lead to the formation of neurotoxic plaque in in human brain, causing the neuron damaged. This hypothesis is called the amyloid cascade hypothesis.
Accordoing to the different times of onset, AD can be categorized into two types: familial and sprodic forms. For the familial type, the early onset of AD is attributed to the gene mutation.Also, it has been reported that the aggregation mechanism of familial Alzheimer’s disease (FAD) is different from others. In addition, the accumulation of Zn2+, Cu2+, Fe3+, and Al3+ is observed when investigating AD patient’s brain tissue, implying that metal ion may be one of the factor that induces the aggregation of Aβ. In our study, we investigated the interaction between Zn2+ or Cu2+ and WT or mutants, and tried to understand the binding coordination between them. First, we expressed and purified 15N labeled Aβ40 WT and mutants for 1H-15N HSQC experiments. Assuming that the cutting efficiency of the TEV protease is 100%, the yield of 15N labeled Aβ is estimated to be around 0.4 mg/L. We concluded that, due to the poor cutting efficiency of our TEV protease, we were not able to successfully separate fusion protein from pure protein using HPLC. Further improvement of our experimental conditions and procedures is needed. Next, we tried to titrate the wild type and mutation form of synthetic Aβ with metal ions and examine the differences using spectrometry and ITC. When interacting with zinc ion,our intrinsic fluorescence and bis—ANS fluorescence results showed that the binding behaviors of H6A and H6R peptides were significantly different from others. Also, we found in our bis-ANS fluorescence results that the hydrophobic exposure area was found to decrease upon binding with copper ion, whereas opposite trend was detected in the case of zinc ion, evidently suggesting that the binding actions of Aβ with copper ion and zinc ion are different. In addition, our CD data indicated that Aβ monomer from NaOH preparation exist mainly in random coil structure and its secondary structure was not considerably influenced by the addition of metal ions. Furthermore, apart from fitting the intrinsic fluorescence data against different model equations to estimate the magnitudes of dissociation constant between Aβ and metal ions, we also compared these estimated values of dissociation constant with the ones obtained from ITC experiment. We found that the total binding equation can best fit our results. The dissociation constant of Aβ with copper and zinc ions were determined to be 3.86 and 4.26 μM, respectively, which are very close to the values, 3.79 and 4.27μM, obtained from ITC measurements. In summary, our study showed that, while H6 mutants have siginifcatly different titration behavior from others, further confirmation is still needed to verify whether the coordination is different or not. We think performing the photo-induced cross-linking of unmodified proteins along with heteronuclear single quantum coherence spectroscopy can certainly aid in better understanding the underlying binding mechanism(s). | en |
dc.description.provenance | Made available in DSpace on 2021-05-17T10:18:09Z (GMT). No. of bitstreams: 1 ntu-100-R99524035-1.pdf: 2457291 bytes, checksum: d8c7eb341093c2e49a75774194f31391 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 誌謝 I
摘要 II Abstract IV 目錄 VI 表目錄 X 圖目錄 XI 第一章 緒論 1 第二章 文獻回顧 2 2-1 神經退化性疾病(neurodegenerative disease) 2 2-1-1 類澱粉症(Amyloidosis) 2 2-1-2 阿茲海默症 4 2-1-3 類澱粉前驅蛋白(amyloid precursor protein,APP)與β-類澱粉蛋白之形成 5 2-1-4類澱粉蛋白致病假說(amyloid cascade hypothesis) 與β-類澱粉蛋白之聚集 7 2-1-5 家族性阿茲海默症(Familial alzheimer’s disease) 9 2-1-6 金屬離子對阿茲海默症之影響 12 2-2 蛋白質檢測方法簡介與原理 16 2-2-1 自身螢光光譜 16 2-2-2 Bis-ANS螢光光譜 18 2-2-3 圓二色光譜 19 2-2-4 恆溫滴定量熱儀 21 2-2-5 核磁共振圖譜 22 2-2-6 蛋白質膠體電泳(polyacrylamide gel electrophoresis, PAGE) 23 2-2-7 蛋白質免疫轉漬法(immunoblotting) 24 2-2-8 蛋白質定量法 25 2-2-9 光誘導交聯法(photo-induced cross-linking of unmodified proteins, PICUP) 27 第三章 研究動機 28 第四章 實驗裝置、藥品與步驟 29 4-1 實驗儀器 29 4-2 實驗藥品 30 4-3 實驗步驟 32 4-3-1溶液配製 32 4-3-1-1 HEPES buffer配製 32 4-3-1-2 Tris buffer配製 32 4-3-1-3 金屬離子溶液配製 32 4-3-1-4 β-類澱粉蛋白單體溶液配製 32 4-3-1-5 LB broth配製 33 4-3-1-6 M9 broth配製 33 4-3-1-7 Lysis buffer配製 33 4-3-1-8 TBST溶液配製 33 4-3-1-9 Transfer buffer配製 34 4-3-1-10 Tricine-SDS-PAGE buffer配製 34 4-3-1-11 FPLC buffer配製 35 4-3-1-12 HPLC buffer配製 35 4-3-2 以自身螢光觀察金屬離子與β-類澱粉蛋白及其突變種之鍵結關係 36 4-3-3 以Bis-ANS螢光觀察金屬離子與β-類澱粉蛋白及其突變種之鍵結關係 36 4-3-4以圓偏極光觀察金屬離子與β-類澱粉蛋白及其突變種之鍵結關係 37 4-3-5 以恆溫滴定量熱儀觀察金屬離子與β-類澱粉蛋白及其突變種之鍵結關係 37 4-3-6 以二維異核化學位移相關光譜觀察金屬離子與β-類澱粉蛋白及其突變種之鍵結關係 37 4-3-6-1 pET14b-Aβ40質體抽取 37 4-3-6-2 以定點突變(site-directed mutagenesis)獲得突變型pET14b-Aβ40表現型菌株 38 4-3-6-3 含有15N標記之原生型/突變型重組Aβ40蛋白的表現及純化 39 4-3-6-4以SDS-聚丙烯醯胺膠體電泳(SDS-PAGE)進行蛋白質成份分析 41 4-3-6-5 以免疫轉漬法(immunoblot)分析蛋白質之成分 42 4-3-6-6 以Bradford assay定量蛋白質濃度 43 4-3-7 以光誘導交聯法檢驗蛋白質形成寡體差異性 44 4-3-8以自動滴定儀進行去摺疊及再折疊實驗 44 第五章 實驗結果與討論 45 5-1 β-類澱粉蛋白單體溶液配製 45 5-2 鋅、銅離子對原生型及突變型β-類澱粉蛋白單體滴定之自身螢光光譜 48 5-3 鋅、銅離子對原生型及突變型β-類澱粉蛋白單體滴定之Bis-ANS光譜 59 5-4 鋅、銅離子對原生型及突變型β-類澱粉蛋白單體滴定之圓二色光譜 66 5-5不同方法獲得之滴定曲線比較與自身螢光滴定曲線之fitting 69 5-6 以恆溫滴定量熱儀測量鋅、銅離子與原生型及突變型β-類澱粉蛋白之結合常數 86 5-7 15N labeled原生型及突變型β-類澱粉蛋白之表現與純化 102 5-7-1 藉由定點突變獲得突變型pET14b-Aβ40質體 102 5-7-2 15N labeled原生型及突變型β-類澱粉蛋白之表現與純化 103 第六章 結論與建議 108 6-1 15N- Aβ40之生產與純化 108 6-2 以光譜法檢測原生型及突變型β-類澱粉蛋白與金屬之結合關係 109 6-3 以恆溫滴定量熱儀檢測原生型及突變型β-類澱粉蛋白與金屬之結合關係 110 6-4 建議及未來展望 110 附錄 111 附錄A 利用Quick Change Primer Design Program設計引子 111 附錄B 以自動滴定儀進行去摺疊與再折疊實驗 113 附錄C TEV-Aβ40-pET14b質體之序列 117 附錄D 自身螢光滴定曲線與Total binding fitting曲線 118 附錄E 縮寫表 130 參考文獻 131 | |
dc.language.iso | zh-TW | |
dc.title | 探討鋅離子及銅離子對於與阿茲海默症N-端突變家族性遺傳相關乙型類澱粉胜肽之鍵結性質 | zh_TW |
dc.title | Investigating the binding properties of Zn2+ and Cu2+ to beta-amyloid peptide with familial N-terminal mutations | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 陳韻如(Yun-Ru Chen) | |
dc.contributor.oralexamcommittee | 陳佩燁(Pei-Yeh Chen),楊定一(Ding-Yi Yang),林達顯(Ta-Hsien Lin) | |
dc.subject.keyword | β-類澱粉蛋白,金屬離子,光譜法,滴定曲線, | zh_TW |
dc.subject.keyword | β-amyloid,metal ions,spectrometry,titration curve, | en |
dc.relation.page | 136 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2012-08-17 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 化學工程學研究所 | zh_TW |
顯示於系所單位: | 化學工程學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf | 2.4 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。